SNDX → $38.80 by Feb 7, 2026.

Hello, I'll get to the chase and I'll try to keep it short. No AI usage (Only for formatting so it's easier to read), however do your own DD. My position is 311 contracts of 2026 OTM calls and planning to add more. https://i.imgur.com/U3hXCUd.png --- **TLDR:** - Small-cap oncology / hematology biotech that now has two commercial products: **Revuforj® (revumenib)**, a menin inhibitor for select AML patients, and **Niktimvo™ (axatilimab-csfr)** (co-developed with Incyte) for chronic GVHD. - Has over **$456 …